Dubbels R, Kattner E, Sell-Maurer D, Schloot W
Arzneimittelforschung. 1980;30(9):1574-9.
Drug acetylation polymorphism is of clinical importance in slow and rapid acetylators. There are therapeutic and toxic consequences of interindividual drug acetylation of, e.g. isoniazid, procainamide and various sulfonamides. For comparing pharmacokinetic and pharmacogenetic data it is necessary to establish a useful model in experimental animals: 1. We determined the half-lives of isoniazid and sulfadimidine in man and rats using a simple loading test and we compared these data with those of in vitro acetylation. In man the half-lives of both substances correlate very well and correspond to acetylation values in vitro. 2. There is no sufficiently good correlation of sulfadimidine concentration in blood and saliva. Furthermore we found no strict correlation between drug concentration in venous and capillary blood. This should be should be considered in pharmacogenetic research. 3. The sulfadimidine half-lives in male Sprague-Dawley and Wistar rat are similar. Both half-lives and acetylation rates in vivo are normally distributed. Sulfadimidine half-lives and the rate of acetylation in vitro do not correlate. Compared with human values the investigated rats are rapid acetylators. Young rats reach their total acetylation capacity in vivo 65 days post partum. 4. Many organs of the rat acetylate sulfadimidine (kidney, lung, intestinal mucosa) with the exception of the spleen. 5. Excess substrate inhibits acetylation of sulfadimidine in vitro. Results of further inhibition studies suggest two or more N-acetyltransferases. 6. Isoniazid inhibits the sulfadimidine acetylation in rat liver homogenates and vice versa. To sum up all data, Sprague-Dawley and Wistar rats seem to be a useful model for human sulfadimidine metabolism pharmacokinetic and, in part, pharmacogenetic studies. Furthermore drug analysis in human saliva can be helpful in pharmacogenetic and pharmacokinetic research in the future.
药物乙酰化多态性在慢乙酰化者和快乙酰化者中具有临床重要性。异烟肼、普鲁卡因胺和各种磺胺类药物等个体间药物乙酰化存在治疗和毒性后果。为了比较药代动力学和药物遗传学数据,有必要在实验动物中建立一个有用的模型:1. 我们使用简单的负荷试验测定了人和大鼠体内异烟肼和磺胺嘧啶的半衰期,并将这些数据与体外乙酰化数据进行了比较。在人体中,这两种物质的半衰期相关性很好,且与体外乙酰化值相符。2. 血液和唾液中磺胺嘧啶浓度的相关性不够好。此外,我们发现静脉血和毛细血管血中的药物浓度之间没有严格的相关性。这一点在药物遗传学研究中应予以考虑。3. 雄性斯普拉格-道利大鼠和Wistar大鼠体内磺胺嘧啶的半衰期相似。体内半衰期和乙酰化率均呈正态分布。磺胺嘧啶的半衰期与体外乙酰化率不相关。与人类值相比,所研究的大鼠是快乙酰化者。幼鼠在产后65天达到其体内总乙酰化能力。4. 除脾脏外,大鼠的许多器官(肾脏、肺、肠黏膜)都能使磺胺嘧啶乙酰化。5. 过量底物在体外抑制磺胺嘧啶的乙酰化。进一步的抑制研究结果提示存在两种或更多种N-乙酰转移酶。6. 异烟肼抑制大鼠肝匀浆中磺胺嘧啶的乙酰化,反之亦然。综上所述,斯普拉格-道利大鼠和Wistar大鼠似乎是研究人类磺胺嘧啶代谢药代动力学以及部分药物遗传学的有用模型。此外,未来人体唾液中的药物分析可能有助于药物遗传学和药代动力学研究。